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DNA microarrays can be used to measure the steady state
m R N Al e v e lo fm o s to ra l lg e n e so fac e l la n dd e l i v e raq u a n -
tiﬁcation of the transcriptional proﬁleon a genomwide scale.
Thepromises thatcomealong withthis newtechnology area
rapidaccesstomolecularpathwaysinbiology,amoreprecise
diagnosis and prognosis of diseases, a better understanding
of drug action, the ability to better deﬁne therapeutic strate-
gies,andmanymore.DNAmicroarraysmayalsobuildanew
bridge on which biologists and clinicians can meet and bring
to fruition what has been termed “translational medicine”
for the beneﬁt of patients.
DNA microarrays are built with snippets of DNA repre-
senting almost the entire genetic information of an organism
on a few square centimeters. They are commercially available
or can readily be made in laboratories with the right equip-
ment. No matter whether oligonucleotides are synthesized
on glass by a sophisticated technology ﬁrst developed for the
semiconductor industry or whether longer PCR products are
simply dotted onto solid surfaces, the scientiﬁc community
h a san e wa n dp o w e r f u lt o o lt om e a s u r eg e n ea c t i v i t y .T ou n -
cover correlations between biological phenomena or medical
conditions and genetic regulatory mechanisms, researchers
no longer have to rely on single gene analysis. However, the
availability of DNA microarrays not only opens the door to
newtypesofexperimentsbutalsodeliversanewtypeofdata.
Comparing the expression level of thousands of genes at the
sametimecannotbecarriedoutwiththesameskillsrequired
to correctly interpret autoradiograms. Computer power, the
right software, and the advice of experts in the bioinformatic
ﬁeld will be necessary.
The possibilities and promises of DNA microarrays are
more than numerous. Cancer research was the ﬁrst promi-
nent ﬁeld that used the new technology. Over 20 years of ba-
sic research have laid the ground for a molecular concept of
cancerasa“geneticdisease.”Butitalsodemonstratedtheim-
mense complexity of each of the over 100 diﬀerent diseases
that can be classiﬁed under the general term “cancer.” Now,
expression proﬁling of tumors with DNA microarrays will
help to better deﬁne a particular tumor type and distinguish
itfromothers.Theﬁrstexperimentshavealreadypointedthe
way: gene expression proﬁles of tumor samples have been
correlated with clinical parameters. The goal is clear: with
the help of cluster algorithms, every tumor should be labeled
withamolecularsignaturedrawnfromnumerousexpression
proﬁles.
By the same token, DNA microarrays will be used to as-
sess the eﬀects of drugs on the transcriptional activity of tar-
get cells or tissues. For basic researchers this should be of im-
mense help to understand processes such as drug induced
apoptosis, drug induced DNA damage and repair, or other
more general aspect of gene regulation by small molecules.
For the pharmaceutical industry, a correlation between gene
activity and eﬀects of candidate compounds may help to
eliminate those with severe side eﬀects before they enter clin-
ical trials. Also, it will help to deﬁne the eﬀects of those drugs
already in clinical use. This application of DNA microarray
technology falls under the roof of a new discipline for which
the label “pharmacogenomics” has already been coined.
Other DNA microarrays willbe, or already have been, en-
gineered that allow to test for the presence of speciﬁc germs
in tissues or body ﬂuids. It will be possible to identify the
bacteria or viruses responsible for infectious disease much
faster and with higher precision than before. Also the traces
that genetically modiﬁed organisms may leave in industrial
food products may be testable on a large scale. Speciﬁcally
designed DNA microarrays, that use “on-chip” PCR reac-
tions for all known genes used for the genetic engineering
of plant and animals in the food industry, are already on the
drawing boards.
Human geneticists will use speciﬁc DNA microarrays
to detect the mutations underlying monogenetic, hereditary
diseases or to interrogate for more general predispositions of
a number of conditions. In addition to gene expression ar-
rays, it is already possible to measure the presence or absence
ofspeciﬁcsinglenucleotidepolymorphisms(SNP)inthehu-
man genome. Researches worldwide and also the Biotech in-
dustry have intensiﬁed their search for human SNPs. Soon
we will be confronted with a database describing all the esti-
mated3millionhumanSNPs.Itmaynotbetoofarfetchedto
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may allow in the future to predict onset, prognosis, and out-
come of diseases that are not yet clinically manifest at the
time of analysis. Moreover, the protagonists of SNP analysis
predict the emergence of a new kind of individual, predictive
medicine; even a revolution in medicine and cancer therapy
is proclaimed. With SNP analysis and gene expression proﬁl-
ing, it should be possible to design individual therapies tai-
lored for a single patient after his/her individual responses
towards drugs, radiation, or other types of therapies.
DNA microarrays are a new and exciting technology.
Similar to all new innovations this technology comes with
many promises for patients, doctors, and researchers alike.
Some of the promises will be kept, some will turn out to
be illusions, and others may turn out to be very diﬃcult to
handle without additional legislation. Cancer classiﬁcation
has begun and the results have already helped to reevaluate
therapy and prognosis in certain cases. Similarly, basic re-
search has proﬁted from the new technology. In this regard,
some promises have been kept. We have to wait and see to
what extent all the other applications of DNA microarray
technology will live up to the their expectations. The new
knowledge of whole organism sequences and the application
of genomic technology as DNA microarrays have opened a
new and exciting era of biology. Despite the large progress
that has been made in understanding biological systems in
the past decades, we are again at a new beginning.
Tarik M¨ or¨ oy
∗ E-mail: moeroey@uni-essen.de